Clinical Trial Update: VX-950-TiDP24-C132: A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Telaprevir. [Phase 1]

View source ↗

Summary

This Phase 1 study evaluated how renal impairment affects the pharmacokinetics of Telaprevir in people with Hepatitis C; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Incivek (Telaprevir) (Telaprevir)

Snippet

Sponsor: Tibotec BVBA | Conditions: Hepatitis C, Kidney Diseases | Phase 1 | Status: COMPLETED